Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trialRandomized Controlled Trial Published on 2022-08-262022-10-05 Journal: Trials [Category] SARS, 임상, [키워드] acute respiratory syndrome adverse event adverse events age antiparasitic drug assigned caused coronavirus coronavirus disease COVID-19 double-blind duration of hospitalization Effectiveness Efficacy enrolment Frequency group hospitalized patient Ivermectin ivermectin treatment Mild Moderate COVID-19 n=36 negativity no difference outbreak overcome pandemic Patient PCR-positive PCR-positive patient Placebo placebo-controlled placebo-controlled trial polymerase chain Primary outcome proportion Randomized Randomized controlled trial Randomly receiving reported reverse transcription RT-PCR SARS-CoV-2 Secondary endpoints secondary outcome shown Side effects significant difference single-center standard care Standard of care survival symptomatic Symptoms therapeutic Treatment Trial worsening [DOI] 10.1186/s13063-022-06649-3 PMC 바로가기 [Article Type] Randomized Controlled Trial
Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study코로나바이러스 질병 2019(COVID-19) 환자 치료를 위한 렘데시비르 플러스 덱사메타손 대 덱사메타손 단독 요법: 보충 O2 요법이 필요한 환자: 전향적 통제된 비무작위 연구Controlled Clinical Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 치료제, [키워드] 30-Day mortality Antiviral baseline calculated clinical outcomes cohorts Combination Controlled coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient CRP D-dimer Dexamethasone drug effective Endpoint enrolled evaluate evaluated faster fibrinogen FiO2 group groups Hospitalization IMPROVE independent Inflammatory inflammatory markers Kaplan-Meier Kaplan-Meier curve Kaplan-Meier curves laboratory characteristics log-rank test median Mortality neutrophil neutrophil/lymphocyte ratio no differences occurred primary endpoint primary endpoints Prospective reducing mortality reduction in reduction in mortality Remdesivir Respiratory failure Respiratory function Sample size SARS-CoV-2 clearance secondary Secondary endpoints shown significant difference significant differences survival the log-rank test therapy treat Treatment viral clearance were used [DOI] 10.1093/cid/ciac014 PMC 바로가기 [Article Type] Controlled Clinical Trial
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trialCOVID-19 회복기 참가자에 대한 FINLAY-FR-1A 백신의 안전성 및 면역원성: 공개 라벨 2a상 및 이중 맹검, 무작위 배정, 위약 대조, 2b상, 심리스, 임상 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI adverse event All participants Alpha anti-RBD antibody assigned Asymptomatic Beta clinical clinical trial clinical trials Complete control group control groups convalescent convalescent individual convalescent individuals COVID-19 criteria Cuba defined delta variant Delta variants dimeric double-blind education elicited ELISA Endpoint enrolled Environment evaluate evaluated experimental group first stage geometric mean geometric mean titre geometric mean titres greater hematology ICTRP IgG antibodies immune response immunogenicity immunology increase in injected injection injection site Intervention intervention group Mild minor Moderate COVID-19 natural immunity Negative PCR neutralisation test neutralising antibody Occurrence Open-label Pain participant Participants PCR test per-protocol population Phase 1 Phase 2 Placebo placebo group placebo-controlled prevaccination Primary outcome Primary outcomes Public randomised Randomly Receptor binding domain recruited Registered registry reported Safety safety analysis safety population safety profile SARS-CoV-2 Science seamless secondary Secondary endpoints Serious Adverse Event Serious Adverse Events seroconversion rate sexual single dose stages study population technology the placebo group titre Trial two groups vaccination Vaccine vaccine immunogenicity Virus neutralisation Volunteer was done WHO-ICTRP [DOI] 10.1016/S2213-2600(22)00100-X PMC 바로가기 [Article Type] Clinical Trial
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial Research Published on 2022-07-212022-10-05 Journal: Nature Medicine [Category] 변종, 임상, 치료제, [키워드] 95% confidence interval Administered administration adverse event approval benefit biopsy cells characteristic clinical disease doses Efficacy Fever Glioblastoma herpes simplex initial investigator-initiated Japan leukopenia lymphocyte lymphocytopenia magnetic resonance imaging nausea occurred Patient patients phase 2 trial prespecified endpoint primary endpoint radiation therapy registry safety profile Secondary endpoints single-arm trial survival survival rate the median therapy Trial virus vomiting [DOI] 10.1038/s41591-022-01897-x [Article Type] Research
Early identification and severity prediction of acute respiratory infection (ESAR): a study protocol for a randomized controlled trial급성 호흡기 감염(ESAR)의 조기 식별 및 중증도 예측: 무작위 대조 시험을 위한 연구 프로토콜Article Published on 2022-07-202022-09-11 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 Acute respiratory infection alarm ARI both groups Clinical diagnosis clinical manifestations clinical trial Consensus Diagnosis diagnostic Efficacy Endpoint enrolled event group Hospitalization in both groups incidence include mechanical ventilation mNGS. multicenter Multiplex PCR non-inferiority Open-label outbreak oxygen participant pathway Patient primary endpoint Prognosis Randomized Randomized controlled trial Randomized controlled trials reached receive resource respiratory infection SARS-CoV-2 secondary Secondary endpoints Severe infection severity Study protocol tested Treatment Treatment outcome Treatment strategies two group two groups [DOI] 10.1186/s12879-022-07552-7 PMC 바로가기 [Article Type] Article
Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia항-CD19 키메라 항원 수용체 T 세포 유도 B 세포 무형성증이 있는 젊은 환자에서 SARS-CoV-2 백신 접종에 대한 면역 반응Article Published on 2022-07-012022-09-11 Journal: Transplantation and cellular therapy [Category] COVID19(2023년), MERS, SARS, 바이오마커, 변종, 진단, 치료기술, [키워드] Acute lymphoblastic leukemia acute respiratory syndrome acute respiratory syndrome coronavirus advent adverse events age Anti-CD19 Anti-CD19 CAR T cell-induced B cell aplasia anti-S Antigen antigen receptor aplasia B cell CAR CAR T cell therapy CD19 CD4 CD4/CD8 Cell therapy cellular immunity chimeric antigen receptor Cohort coronavirus coronavirus disease coronavirus disease 19 COVID-19 Cytometry deficiency diagnosed disease Endpoint Exacerbation exhibited expected flow cytometry grade 3 Graft-versus-host disease GVHD healthy healthy controls humoral Humoral response humoral responses Immune cell immune response Immunoglobulin Immunoglobulin G incidence individual induce Infection leukemia Lymphoblastic leukemia lymphocyte Lymphocyte count Lymphocyte subsets mRNA vaccine Mutation Omicron variant outcome Patient precursor primary endpoint Prospective Study PROTECT protective effect recipient Relapse respiratory response risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination second dose secondary Secondary endpoints Seroconversion severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spike protein subsequent T cell T cell response T cell responses T cells T-cell the patient the vaccine therapy treated vaccination Vaccine [DOI] 10.1016/j.jtct.2022.04.017 PMC 바로가기 [Article Type] Article
Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials2개의 단일 센터 2상 임상 시험에서 CoronaVac의 추가 용량의 6개월 추적Clinical Trial Published on 2022-06-032022-09-12 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] adverse event age Antibody titre booster booster dose clinical trial clinical trials contribute CoronaVac Determining dose double-blind Exploratory endpoints Follow-up follow-up period geometric mean titre GMT GMTs homologous humoral Immunity immunization immunization strategies increases in magnitude neutralising antibody neutralization Older placebo-controlled population immunity post-hoc analyses randomised recommendation recorded regimen Secondary endpoints titre [DOI] 10.1038/s41467-022-30864-w PMC 바로가기 [Article Type] Clinical Trial
Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study염증 표지자가 상승한 입원한 COVID-19 환자에서 토실리주맙의 조기 투여; COVIDSTORM-전향적, 무작위, 단일 센터, 공개 라벨 연구Randomized Controlled Trial Published on 2022-06-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 바이오마커, 임상, 진단, [키워드] (interleukin-6 activities addition administration Admission benefit C-reactive protein clinical clinical recovery clinical status control group control patient control patients COVID-19 D-dimer demonstrated discharged elevated ferritin hospital Hospital admission Hospitalization Hospitalized hospitalized COVID-19 patient Hypoxemia immune response Inflammation inflammation markers Inflammatory inflammatory biomarkers intensive care intensive care unit admission interleukin interleukin-6 interquartile range marker median Open-label Ordinal Scale Patient patients hospitalized primary endpoint Randomized respiratory Respiratory Support SARS-CoV-2 secondary endpoint Secondary endpoints seven-category ordinal scale severe COVID-19 significantly SOC Standard of care TCZ Tocilizumab with COVID-19 [DOI] 10.1016/j.cmi.2022.02.027 PMC 바로가기 [Article Type] Randomized Controlled Trial
CytoSorb Rescue for COVID-19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open-Label, Randomized Controlled Pilot StudyRandomized Controlled Trial Published on 2022-06-012022-10-04 Journal: Critical Care Medicine [Category] 임상, [키워드] 1:1 95% CI adjusted Adsorption adverse event age Antibiotics Berlin C-reactive protein clinical concentrations control group Controlled COVID-19 COVID-19 patient COVID-19 patients cytokine dose Effect Endpoint enrolled excluded Gender greater groups hazard ratio Hemodialysis ICU IMPROVE inflammatory markers interleukin-6 interquartile range IQR junction measurement median membrane Monmouth Mortality mortality rate Multiple one patient Patient pilot study primary endpoint Prospective Randomized receive reduction Registered registry rescue Resolution secondary Secondary endpoints Shock Standard of care Standard therapy study inclusion the primary endpoint treatment group university hospital variable Withdrawal [DOI] 10.1097/CCM.0000000000005493 PMC 바로가기 [Article Type] Randomized Controlled Trial
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19SARS-CoV-2에 대한 아프로티닌 치료: 중등도 COVID-19에 대한 범프로테아제 억제제의 안전성과 효능을 평가하기 위한 무작위 3상 연구Clinical Trial Published on 2022-06-012022-09-11 Journal: European Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] ACE2 addition administration Adverse reaction Adverse reactions anti-inflammatory properties anti-inflammatory property antiviral drug antivirus Aprotinin cleave Clinical outcome clinical trial Composite Contact COVID-19 death discharge double-blind Efficacy evaluate follow-up period furin had no hospital Hospital admission Hospital stay Hospitalization hospitalized patient hospitalized patients host protease host proteases human respiratory viruses ICU admission IMPROVE incidence inhalation therapy inhibiting inhibitor Innate immunity less mechanism Moderate COVID-19 multicentre outcome oxygen Oxygen therapy parameter patients with COVID-19 performed placebo group Pneumonia profiles Protease inhibitor Randomized randomized trial required respiratory viruses resulting Safe Safety SARS-CoV-2 SARS-CoV-2 virus secondary endpoint Secondary endpoints Side effects significant difference significant differences Spanish Spike protein standard treatment the placebo group Treatment with COVID-19 [DOI] 10.1111/eci.13776 PMC 바로가기 [Article Type] Clinical Trial